Birmingham Capital Management Co. Inc. AL Sells 1,025 Shares of Agilent Technologies, Inc. $A

Birmingham Capital Management Co. Inc. AL reduced its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 31.5% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 2,225 shares of the medical research company’s stock after selling 1,025 shares during the period. Birmingham Capital Management Co. Inc. AL’s holdings in Agilent Technologies were worth $263,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in Agilent Technologies by 13.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company’s stock worth $4,279,000 after purchasing an additional 4,362 shares in the last quarter. Alps Advisors Inc. grew its holdings in shares of Agilent Technologies by 29.5% in the first quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company’s stock valued at $1,563,000 after acquiring an additional 3,040 shares in the last quarter. D.A. Davidson & CO. grew its holdings in shares of Agilent Technologies by 30.4% in the first quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company’s stock valued at $1,108,000 after acquiring an additional 2,207 shares in the last quarter. LGT Capital Partners LTD. grew its holdings in shares of Agilent Technologies by 7.6% in the first quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company’s stock valued at $89,870,000 after acquiring an additional 54,302 shares in the last quarter. Finally, Live Oak Investment Partners bought a new position in shares of Agilent Technologies in the first quarter valued at approximately $603,000.

Agilent Technologies Trading Up 0.6%

NYSE:A opened at $142.01 on Monday. The company has a market cap of $40.26 billion, a P/E ratio of 33.34, a P/E/G ratio of 4.63 and a beta of 1.26. The stock’s fifty day moving average price is $127.58 and its two-hundred day moving average price is $117.90. Agilent Technologies, Inc. has a 1 year low of $96.43 and a 1 year high of $153.84. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.37. The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business’s quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, analysts expect that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.248 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.99 annualized dividend and a dividend yield of 0.7%. Agilent Technologies’s dividend payout ratio is currently 23.24%.

Wall Street Analysts Forecast Growth

A has been the subject of several recent analyst reports. Evercore ISI upped their target price on Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a report on Tuesday, October 7th. Robert W. Baird upped their price objective on Agilent Technologies from $141.00 to $142.00 and gave the company an “outperform” rating in a research note on Thursday, August 28th. Rothschild & Co Redburn started coverage on Agilent Technologies in a research note on Wednesday, October 8th. They issued a “buy” rating and a $165.00 price objective on the stock. TD Cowen upped their price objective on Agilent Technologies from $150.00 to $162.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Agilent Technologies in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Agilent Technologies currently has an average rating of “Moderate Buy” and a consensus price target of $149.62.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.